About Lauren Harshman
- Immunotherapy has come of age with the approval of Sipuleucel-T (Provenge) and the introduction of ipilimumab (Yervoy) and other similar immune modulators into clinical trials for advanced metastatic prostate cancer.
- Dr. Harshman will study the biologic activities of a genetically-modified prostate tumor cell vaccine in the setting of Xtandi (enzalutamide) therapy for advanced, metastatic prostate cancer.
- These translational investigations, while developing a new therapy for patients, will also result in a biological understanding of the mechanisms of sensitivity and resistance to immunotherapy for prostate cancer. What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.
What this means for patients: A new immunotherapy will be developed for advanced, metastatic prostate cancer.
2013 PCF Young Investigator
Lauren Harshman, MD
Dana-Farber Cancer Institute
Philip Kantoff, MD and Christopher Sweeney, MBBS
Clinical exploration of innovative targeted and immune modulating therapies in prostate cancer